Reported about 9 hours ago
Absci Corporation (ABSI) has secured $64 million in equity financing to enhance its AI-driven drug discovery initiatives through 2028. The company, which integrates deep learning with lab automation to optimize biologics, aims to advance its key pipeline programs, including treatments for chronic skin diseases and hair loss disorders. Additionally, Absci has expanded its partnerships and strengthened its technology infrastructure in collaboration with companies like Oracle and AMD, reinforcing its commitment to revolutionizing drug discovery.
Source: YAHOO